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Objective: Brugada syndrome (BS) is an inherited electrical cardiac disorder characterized by right bundle branch block pattern and ST
segment elevation in leads V1 to V3 on surface electrocardiogram that can potentially lead to malignant ventricular tachycardia and sudden
cardiac death. About 20% of patients have mutations in the only so far identified gene, SCN5A, which encodes the a-subunit of the human
cardiac voltage-dependent sodium channel (hNav1.5). Fever has been shown to unmask or trigger the BS phenotype, but the associated
molecular and the biophysical mechanisms are still poorly understood. We report on the identification and biophysical characterization of a
novel heterozygous missense mutation in SCN5A, F1344S, in a 42-year-old male patient showing the BS phenotype leading to ventricular
fibrillation during fever.
Methods: The mutation was reproduced in vitro using site-directed mutagenesis and characterized using the patch clamp technique in the
whole-cell configuration.
Results: The biophysical characterization of the channels carrying the F1344S mutation revealed a 10mV mid-point shift of the G/V curve
toward more positive voltages during activation. Raising the temperature to 40.5-C further shifted the mid-point activation by 18mV and
significantly changed the slope factor in Nav1.5/F1344S mutant channels from 6.49 to 10.27mV.
Conclusions: Our findings indicate for the first time that the shift in activation and change in the slope factor at a higher temperature
mimicking fever could reduce sodium currents’ amplitude and trigger the manifestation of the BS phenotype.
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The Brugada syndrome (BS) is an autosomic dominant
inherited cardiac disorder without underlying structural0008-6363/$ - see front matter D 2006 European Society of Cardiology. Publishe
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1 These authors contributed equally to this work.heart disease. The electrocardiographic (ECG) character-
istics of the BS are a right bundle branch block pattern and
ST segment elevation in leads V1 to V3 [1]. Clinically, the
BS manifests by syncope and sudden cardiac death (SCD)
from fast polymorphic ventricular tachycardia (VT) and
ventricular fibrillation (VF). The diagnosis of the BS is
based on this typical ECG pattern, either spontaneously
manifesting or unmasked by sodium channel blockers [2–
4]. The SCN5A gene is so far the only identified gene to be
involved in genetically determined forms of BS and70 (2006) 521 – 529d by Elsevier B.V. All rights reserved.
D.I. Keller et al. / Cardiovascular Research 70 (2006) 521–529522mutations in the SCN5A gene have been identified in 10–
30% of BS in genotyped families [5]. Recently a second
locus on chromosome 3 has been identified [6]. Interest-
ingly, this locus overlaps with the one of SCN5A and the
involvement of SCN5A was excluded by a direct investiga-
tion. This suggests an important heterogeneity in the genetic
background of the BS. The SCN5A gene encodes the a-
subunit of the human cardiac voltage-dependent sodium
channel, hNav1.5. This channel produces a depolarizing
inward sodium current INa and subsequently inactivates
within milliseconds. Mutations in SCN5A are associated
with several cardiac electrical diseases among which the BS,
the Long QT-Syndrome (LQTS) and Lenegre’s disease are
the best characterized. The mechanisms of how SCN5A
mutations lead to different cardiac electrical diseases are still
under investigation. In general, SCN5A mutations leading to
the BS phenotype are associated with a loss of channel
function with a reduction of the Na+ current [7–11]. Indeed,
important qualitative alterations of the activation/inactiva-
tion mechanisms of the current may be involved. Clinically,
the role of fever in unmasking the BS and triggering
arrhythmias is of great importance [12–15]. However the
underlying mechanisms remain unclear. Only few mutations
leading to an exacerbation of the BS phenotype during fever
have been studied functionally, and more data is needed to
unravel and understand this important factor. The aim of this
study was to investigate a family with the BS triggered by
fever, to screen the SCN5A gene for mutations and to study
the effects of the mutation on the channel function in an in
vitro model.2. Methods
2.1. Clinical evaluation
Subjects II-1 (index patient), III-1, III-2, III-3, III-4
underwent detailed clinical examinations including baseline
12-lead ECG and echocardiography. To unmask the
Brugada ECG, subject II-1 received flecainide i.v. (2mg/kg
body weight) [5]. Subjects III-1, III-2, III-3 and III-4 did not
undergo flecainide testing (declined by parents).
2.2. Molecular genetics
The study was performed according to the guidelines of
the Declaration of Helsinki. Family members participating
in the study gave written informed consent. Genomic DNA
was extracted from peripheral lymphocytes. In the index
patient, subject II-1, all coding exons of SCN5A were
amplified by polymerase chain reaction (PCR) using
primers designed in intronic flanking sequences according
to the gene sequence described by Wang et al. [16]. The
PCR products were directly sequenced using a big dye
termination mix and analyzed by cycle sequencing using an
automated laser fluorescent DNA sequencer (ABI Prism377, Applied Biosystems, Foster City, CA, USA). In
subjects III-1, III-2, III-3, and III-4, exon 23 was directly
amplified by PCR and sequenced in both strands as
described above.
2.3. Mutagenesis
Mutant hNav1.5/F1344S was generated using a Quick-
Change TM site-directed mutagenesis kit according to the
manufacturer’s instructions (Stratagene, La Jolla, CA,
USA), using the following nucleotide mutagenic sense and
antisense primers:
5V-C GTC CTC CTC GTC TGC CTC ATC TCC TGG
CTC ATC TTC AGC ATC ATG G-3V
5V-CC ATT GAT GCT GAA GAT GAG CCA GGA GAT
GAG GCA GAC GAG GAG GAC G-3V
The mutated site is underlined. Mutant and wild-type
(WT) Nav1.5 channels in a pcDNA1 construct were purified
using Qiagen columns (Qiagen Inc., Chatsworth, CA, USA).
2.4. TsA201 cell line transfection
The tsA201 cell line is a mammalian cell line derived
from human embryonic kidney HEK 293 cells by stable
transfection with SV40 large T antigen [17]. The tsA201
cells were grown and transfected using the calcium
phosphate method as already described [17] with the
following modification to facilitate the identification of
individual transfected cells: a co-transfection with an
expression plasmid for a lymphocyte surface antigen
(CD8-a) was performed [18]. The human Na+ channel h1-
subunit and CD8 were constructed in the piRES vector
(piERS/CD8/h1). Using this strategy, transfected cells that
bind beads (Dynal A.S., Oslo, Norway) also express the h1-
subunit and are visually distinguishable from nontransfected
cells by light microscopy.
2.5. Patch clamp method
Macroscopic Na+ currents from tsA201-transfected cells
were recorded using the whole-cell configuration of the
patch clamp technique [19]. Patch electrodes were made
from 8161 Corning borosilicate glass and coated with
Sylgard (Dow-Corning, Midland, MI, USA) to minimize
their capacitance. Patch clamp recordings were made using
low resistance electrodes (<1MV), and a routine series
resistance compensation by an Axopatch 200 amplifier
(Axon Instruments, Foster City, CA, USA) was performed
to values >80% to minimize voltage-clamp errors. Voltage-
clamp command pulses were generated by microcomputer
using pCLAMP software v8.0 (Axon Instruments). Na+
currents were filtered at 5kHz, digitized at 10kHz and
stored on a microcomputer equipped with an AD converter
(Digidata 1300, Axon Instruments). Data analysis was
Fig. 1. (A) 12-lead ECG during fever 39.2-C, showing coved ST segment elevation in the right precordial leads. (B) Fast non-sustained ventricular tachycardia
during fever at a temperature of 39.2-C (indicated by arrow). (C) Normal 12-lead ECG in the absence of fever.
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(Axon Instruments), Microsoft Excel, and SigmaPlot 2001
for Windows version 7.0 (SPSS Inc., Chicago, IL, USA).
For temperature studies, the bath solution was heated
using a bipolar temperature controller (Model: TC-202)
from Medical systems Corp., Greenvale, N.Y. USA. The
temperature was measured as close as possible to the cell
using a Barnant thermistor thermometer.Fig. 2. (A) Sequencing revealed a T to C base change in exon 23 of SCN5A gene in
heterozygous state. (B) Family pedigree. Index patient II-1 shows the BS phenotyp
of the four daughters are carriers of the mutation, their baseline ECGs are norma
black circles, indicating a positive genotype but negative phenotype). Four broth2.6. Solutions and reagents
For whole-cell recordings, the patch pipette contained
35mM NaCl, 105mM CsF, 10mM EGTA, and 10mM Cs–
HEPES. The pH was adjusted to 7.4 using 1N CsOH. The
bath solution contained 150mM NaCl, 2mM KCl, 1.5mM
CaCl2, 1mM MgCl2, 10mM glucose, and 10mM Na–
HEPES. The pH was adjusted to 7.4 with 1N NaOH. Athe patient compared to the control, resulting in the F1344S mutation at the
e and is carrier of the F1344S SCN5A mutation (black filled square). Three
l, flecainide testing to unmask the BS phenotype was not performed (semi
ers of the index patient II-1 died suddenly.
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the patch pipette and the bath solutions was performed. The
recordings were made ten minutes after obtaining the
whole-cell configuration in order to allow the current to
stabilize and achieve adequate diffusion of the contents of
the patch electrode and minimize the shift of gating
observed under these conditions [20]. Experiments were
carried out at either room temperature (22–23-C) or at
40.5-C to simulate fever.
2.7. Statistical analysis
Data are expressed as meansTS.E.M. (standard error of
the mean). Where indicated, a t-test was performed using
statistical software in SigmaPlot (Jandel Scientific Software,
San Rafael, CA, USA). Differences were considered
significant when the P value was <0.05.Fig. 4. (A) The mean current–voltage (I/V) relationships expressed as
current density, where the amplitude of Na+ currents were normalized to
the cell capacitance and plotted versus the applied voltage. Similar
protocol used as shown in Fig. 1, were used here (see inset); *P <0.05 and
**P <0.01. (B) The voltage dependence of steady-state activation (G/V) of
Nav1.5/WT compared to the one obtained from Nav1.5/F1344S, con-
structed from the I/V shown on panel (A). The data points of the G/V
curve were fitted using a Boltzmann equation with V1/2 and Kv
representing, respectively, the slope factor and the half-maximum voltage
of activation: I/Imax=1/(1+exp(VV1/2/Kv)), Imax represents the maxi-
mum current.3. Results
3.1. Brugada syndrome phenotype during fever
The index patient II-1, a 42-year-old construction worker,
presented to the emergency room with fever 39.2-C, cough
and pleuritic pain. Before his admission to the hospital, he
had taken paracetamol and phenylephrin p.o., but no other
drugs, particularly no antidepressants or other QT-interval
prolonging medications. Diagnosis of pneumonia was made
in the hospital. His 12-lead ECG recorded during high fever
(39.2-C) showed the characteristic Brugada type 1-changes
[21] with coved-type ST segment elevations in V1–V2 (Fig.
1A). Polymorphic non-sustained VT were registered (Fig.
1B), and the patient received atenolol 12.5mg p.o. and
magnesium i.v. Twenty-five minutes later, he developed VF
requiring two defibrillations. Under antipyretic therapy,
repolarization normalized in the right precordial leads and
there were no further ventricular arrhythmias (Fig. 1C).
Antibiotic therapy with piperacillin/tazobactam was initiatedFig. 3. The family of whole-cell sodium current traces from (A) Nav1.5/WT and
generated from a holding potential of 140mV from 80 to +50mV during 50after resuscitation. A flecainide challenge unmasked the BS
type 1 phenotype (ECG not shown). After treatment of his
pneumonia, a cardioverter-defibrillator (ICD) was
implanted. ICD interrogation during a 28-month follow-up
showed no episodes of VT/VF.from (B) Nav1.5/F1344S expressed in the tsA201 cell line. Currents were
ms in 10-mV increments as shown in inset.
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family screening
We identified a novel missense mutation, F1344S, in
SCN5A in the index patient II-1 by direct DNA sequencing
(Fig. 2A). A heterozygous T to C base change at position
4031 in exon 23 resulted in the change of Phenylalanine
(TTC) to Serine (TCC) in residue 1344. The mutation was
located in the DIII-S5 transmembrane region of the Nav1.5
sodium channel, a region highly conserved in many Na
channels from different species (data not shown). In the
index patient, we found the following common polymor-
phisms in SCN5A (all at the homozygous state): C280C
(T840C), R552G (C1654G), Q1027R (A3080G) and
D1819D (C5457T). The H558R polymorphism, which is
supposed to modulate the biophysical properties and the
trafficking of SCN5A in the presence of other mutations,
was absent in our patient [22,23].
The four daughters of the patient were screened clinically
and genetically (Fig. 2B). Subject III-1 is a 15-year-old girl
with a normal baseline ECG and normal echocardiography.
She suffers from recurrent syncope occurring several times
per year usually after getting up in the morning or related to
periods of sleep deprivation. She never had a syncope
during fever. Genetic testing revealed the F1344S mutation.
Subject III-2 is a 12-year-old girl without history of
syncope, with normal ECG and normal echocardiography.
She does not carry the F1344S mutation. Subject III-3 is a 9-
year-old girl with a history of one syncope during school
class, and with normal ECG and echocardiography. She is
also a carrier of the F1344S mutation. The fourth child is a
4-year-old girl (III-4) who never had syncope and has
normal ECG. She also carries the mutation. Unfortunately,
the parents declined flecainide testing in the children
carrying the mutation. Family history revealed that fourTable 1
Biophysical parameters of Nav1.5/WT and Nav1.5/F1344S
23-C
Nav1.5/WT Nav1.5/F1344S
Steady-state activation
V1/2 (mV) 60.16T1.42 (n =10) 50.43T2.03**n =9
Kv (mV) 6.33T0.33 (n =10) 6.99T0.52 (n =9
Steady-state inactivation
V1/2 (mV) 103.82T0.64 (n =8) 104.47T0.93 (n =9
Kv (mV) 5.61T0.07 (n =8) 4.65T0.06 (n =9
Slow inactivation
s (ms) 251.25T32.37 (n =8) 220.11T29.89 (n =
Recovery from inactivation
s (ms) 22.43T1.60 (n =8) 17.60T1.88* (n =
V1/2=Mid point for activation or inactivation.
Kv= slope factor.
s =time constant.
* P <0.05.
** P <0.01.brothers of the index patient died between the age of
6months and 3years. The cause of death is not clear as the
family lives abroad. The mother of the index patient died
from lung disease; the father lives abroad and could not be
tested.
3.3. Biophysical characteristics of Nav1.5/F1344S mutant
Na+ channels
3.3.1. Macroscopic Nav1.5 recordings and current densities
Macroscopic Na+ currents were recorded first at room
temperature from tsA201 cells expressing either WT
(Nav1.5/WT) or mutant channels (Nav1.5/F1344S) co-trans-
fected with the h1-subunit. The resulting Nav1.5/WT and
Nav1.5/F1344S Na
+ currents showed fast activation and
inactivation kinetics (Fig. 3). Current densities in pA/pF for
the WT and Nav1.5/F1344S mutant channels measured from
cells that were transfected with equal amount of DNA were
not statistically different (Fig. 4A). However, the potential at
which Na current appears was shifted to more positive
potentials. This resulted in a shift of the G/V curve (steady-
state activation) of about 10mV to more positive potentials
with no statistical changes in the slope factor for F1344S
mutation (see Table 1 for parameters).
Steady-state inactivation was also studied using a double
pulse protocol (Fig. 5A). No significant shifts in either half
inactivation (V1/2) or slope factor were observed on mutant
channels compared to the WT channels. The recovery from
inactivation studied at 120mV using a two-pulse protocol
shows a rapid recovery (Fig. 5B) (see Table 1 for
parameters).
Entry to slow inactivation was shown to be affected in
BS mutant channels, however, the slow inactivation of
Nav1.5/F1344S mutation was not statistically significant
from WT (Fig. 6A).40.5-C
Nav1.5/WT Nav1.5/F1344S
) 60.69T2.60 (n =9) 42.44T2.7** (n =5)
) 6.49T0.67 (n =9) 10.27T0.80** (n =5)
)
)
9)
9)
Fig. 5. (A) Steady-state availability curve was determined by using 500ms
conditioning pulses to voltages between 140 and 30mV to a standard
test pulse to either 30mV (see inset). Test currents were normalized and
plotted versus conditioning voltage. (B) Recovery from fast inactivation
obtained using a double pulse protocol (see inset). A standard test pulse was
used to monitor recovery, and the normalized test currents were plotted
versus the recovery interval.
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tudes was studied at frequencies found during fever in
comparison with a normal frequency of stimulation. As
expected since the recovery from inactivation was faster in
the presence of the mutation, the currents were larger at
higher frequency of stimulation, exhibiting a resistant to
block (Figs. 6B and 7).
3.3.2. Effect of temperature on channel properties
When macroscopic Na+ currents were recorded at
temperatures up to 40.5-C, no effect was seen on mutant
Nav1.5/F1344S channels compared to WT channels (Fig. 8,
upper panel).
As expected, rising the temperature from 22 to 40.5-C
markedly increased the rate of inactivation for WT and
F1344S mutant channels (Fig. 8B and C). There was also no
effect on activation of WT channels at 23-C and 40.5-C
(parameters not shown). In contrast activation curves
showed an 8mV shift of activation towards more positivepotential with a significant change in the slope factor for
mutant Nav1.5/F1344S channels measured at 40.5-C versus
23-C (Fig. 8D). Indeed, changes in temperature resulted in a
further shift of the voltage-dependent activation curves
towards more positive voltages with a significant effect on
the slope factor (Fig. 8D) for F1344S mutation at 40.5-C
(see Table 1 for parameters). Although the figure shows a
slight increase in current amplitudes, the maximum current
densities at 40.5-C were not statistically significant from the
one recorded at room temperature (data not shown).4. Discussion
It is well recognized that the ECG patterns of ST segment
elevation in the right precordial leads in patients with BS are
inconstant and can be revealed by external factors such as
medication and fever [14,24–26]. Although the effect of
drugs such as class 1 antiarrhythmic’s, cocaine and
antidepressant is probably related to the blockade of sodium
channels, the molecular and the ionic mechanisms related to
the effect of fever remain elusive.
We report a novel SCN5A mutation, F1344S, in a family
with BS phenotype, associated in the index patient with
fever-triggered VF. This mutation results in a loss of Na+
channel function by shifting the steady-state activation
towards more positive potentials. The analysis of the mutant
channels in heterologous expression system (tsA201 cell
line) reveals normal kinetics of inactivation but a shift in
activation that could potentially reduce the availability of
sodium channels. A shift of the activation curve was found
to underlay several BS mutations [27]. As the index patient
developed the BS phenotype only during fever we studied
the effect of the mutant Nav1.5/F1344S channel properties
at different temperatures. Activation curves showed the
10mV shift of activation towards more positive potential at
40.5-C as noted at normal baseline experimental tempera-
ture of 23-C. Interestingly, in addition to the shift of
activation, we found a significant change in the slope factor.
The slope was less steep for mutant Nav1.5/F1344S
channels at 40.5-C compared to the one measured at
23-C. Apart from the BS, fever was identified as a
precipitant of idiopathic VF in a series of patients with
structurally normal hearts [28]. In the study of Pasquie et al.
temperature-dependent modification of ion channel proper-
ties or expression were proposed to facilitate spontaneous
activity within the right ventricular outflow tract or the
Purkinje system as a potential mechanism to initiate VF.
In the present study, for the first time we show that the
effect of temperature can be related to a further shift in ac-
tivation with a reduced slope factor, suggesting that the ac-
tivation energies are markedly reduced in the presence of this
specific mutation. Moreover, the F to S mutation may have a
large effect on the structure of channel proteins since F is com-
pletely hydrophobic and S it may H-bond with neighboring
amino acid residues because of the presence of an OH group.
Fig. 6. (A) Development of slow inactivation of Nav1.5/WT and Nav1.5/F1344S sodium channels. Time course of entry into the slow inactivated state was
measured by using a triple-pulse protocol consisting of a variable duration conditioning pulse (2ms to 1s) to 30mV to inactivate the channels. A 20-ms inter-
pulse to 140mV was applied to promote the rapid recovery of inactivated channels, and a standard test pulse was used to assay availability (see inset). The
test currents were normalized and plotted versus the conditioning pulse interval (Nav1.5/WT, ˝; Nav1.5/F1344S, &). (B) Frequency-dependent inhibition of
Nav1.5/WT and Nav1.5/F1344S sodium currents. A train of 50 pulses was applied to 10mV (Nav1.5; n =9) or 10mV (Nav1.5/F1344S; n =11) at
frequencies between 5 and 50Hz. The peak currents elicited by each test pulse were normalized to the current of the first pulse ( Pn/P1, where n =1–50) and
were plotted versus the pulse number (see inset). The pulse duration was 8ms. The holding and interpulse potentials were 120mV.
D.I. Keller et al. / Cardiovascular Research 70 (2006) 521–529 527Fever is usually associated with sinus tachycardia, which
is a confounding factor. Indeed, the index patient had a heart
rate of 103bpm. Therefore, we studied the effect of varying
the frequency of stimulation on Na+ current amplitudes. In
contrast to WT channels, Na currents show even a resistant
to block at high frequency of stimulation, probably due toFig. 7. (A) Ratio of the currents elicited by the 50th and first pulses ( P50/P1) ve
Nav1.5/WT (B) and Nav1.5/F1344S (C) stimulated at 20Hz.the fast recovery from inactivation. We found that the
currents were increased at higher frequency of stimulation.
Thus, a raise in heart rate seems not to be contributing to the
risk for developing VT in patients carrying this particular
mutation. This apparent gain of function will not result in a
rescue of the loss of function due to the shift of activation.rsus the pulsing frequency. (B and C) Representative raw current traces of
Fig. 8. Effect of temperature on Nav1.5/WT and Nav1.5/F1344S current and G/V curves. No differences in macroscopic Na
+ currents recordings for WT and
mutant currents at 40.5-C temperature (B–C). (D) Further shift of activation curves toward more positive voltages with a significant (*P <0.05) effect on the
slope factor in mutant currents at 40.5-C. The data point of the G/V curve were fitted using a Boltzmann equation.
D.I. Keller et al. / Cardiovascular Research 70 (2006) 521–529528The F1344S mutation segregated to three of the four
daughters. Four brothers of the index patient died suddenly
at a very young age. It is possible that they were carriers of
the F1344S mutation, suggesting a malignant course.
Unfortunately no data on their phenotypes are available.
Several antibiotics and antidepressant such as tricyclic
antidepressants are known to induce torsades de pointes by
QT-interval prolongation or BS, respectively. One could
speculate that the antibiotic agent may have influenced the
repolarization of the mutant channels. Piperacillin/tazobac-
tam is not known to prolong the QT-interval (www.torsa-
des.org) and we do not further followed this hypothesis, also
because the drug was administered after the initiation of VF.
Before hospital admission, the patient took phenylephrin
p.o. It is not known whether phenylephrin has the potential
to unmask the BS phenotype and might have contributed to
trigger VF.
In this patient and in his daughters carrying the F1344S
SCN5A mutation, future episodes of fever should be
aggressively treated with antipyretic agents whereas beta-
blockers and phenylephrin should be completely avoided.5. Conclusion
We identified a novel mutation in SCN5A, F1344S, in a
patient with the BS and fever-induced VF. In our in vitro
model we found that the mutation resulted in a loss of
sodium channel function, as previously described for other
SCN5A mutations leading to the BS. For the F1344S
mutation, the mechanism was most probably a loss of
function due to the shift of activation. Temperaturesimulating fever resulted in a further shift of activation
and a reduction in the slope factor. Taken together, our
findings indicate that the shift in activation and change in
the slope factor at higher temperature mimicking fever could
reduce sodium currents availability and trigger the manifes-
tation of the BS phenotype. Fever should be vigorously
treated with antipyretics in patients with fever-induced BS.Acknowledgements
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